Shen Y, Chen X, Zhang H, Hu H. Long-term cost-effectiveness analysis of onceweekly Semaglutide versus Dulaglutide for the treatment of type 2 diabetes after the renewal of the national drug reimbursement list in China. Health Decision. 2024;2(S1). doi:10.54844/hd.2024.0003